H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while ...

Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® ...

Invivyd Inc (NASDAQ:IVVD) has internalized its commercial organization, which is expected to drive broader adoption of PEMGARDA and improve commercial results. The company has secured access to ...

Thank you for standing by. And welcome to Invivyd’s First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there ...

INVIVYD ($IVVD) posted quarterly earnings results on Thursday, May 15th. The company reported earnings of -$0.14 per share, missing estimates of -$0.03 by $0.11. The ...

INVIVYD ($IVVD) is expected to release its quarterly earnings data on Thursday, May 15th before market open, per Finnhub. Analysts are expecting revenue of ...

May 12, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs ...

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that ...

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD – Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $10.00 price ...

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist ...